Nurix Therapeutics, Inc. · NASDAQ:NRIX

Nurix Therapeutics — Investor Presentation (September 2025)

12 slides from Nurix Therapeutics's investor presentation, Sep 3, 2025

  1. Slide 1: Protein Degraders to Outmatch Cancer and Autoimmune Disease

    Protein Degraders to Outmatch Cancer and Autoimmune Disease Investor Presentation September 2025

  2. Slide 2: Important Notice and Disclaimers

    Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipa

  3. Slide 3: Targeted Protein Degradation: Leading the Next Frontier in Drug Development

    Targeted protein degradation (TPD) Leading the Next Frontier in Drug Development 3 Evolution of new therapeutic modalities AntibodiesSmall molecule inhibitors Nucleic acid-based therapies (Antisense, RNAi Gene Therapy, CRISPR) Targeted protein degraders

  4. Slide 4: Nurix's Target-Driven Pipeline Strategy

    Focused on clinically validated and high-impact targets Nurix’s Target-Driven Pipeline Strategy BTK, Bruton’s tyrosine kinase; BRAF, v-RAF murine sarcoma viral oncogene homolog B1; I&I, inflammation and immunology; IRAK4, interleukin-1 receptor-associated kinase 4; STAT6, signal transducer and activ

  5. Slide 5: Bexobrutideg – The First "deg" Novel MOA Against a Proven Target

    Bexobrutideg – The First “deg” Novel MOA Against a Clinically and Commercially Proven Target 5  Addresses BTK scaffolding function unlike current BTK inhibitors  Acts catalytically driving degradation at low free-plasma concentrations  Demonstrated robust clinical activity in difficult to treat B

  6. Slide 6: Bexobrutideg Degrades Wild-Type and Mutated BTK

    Bexobrutideg degrades gatekeeper, kinase- proficient and kinase-dead BTK mutations Bexobrutideg Degrades Wild-Type and Mutated BTK Note: Some patients have multiple BTK mutations BTK degradation in CLL patients BTK, Bruton’s tyrosine kinase; CLL, chronic lymphocytic leukemia; GI-50 growth inhibition

  7. Slide 7: Robust Clinical Activity in CLL Patients Regardless of Baseline Mutational Burden

    Robust Clinical Activity in CLL Patients Regardless of Baseline Mutational Burden ATM, Ataxia-telangiectasia mutated; BTK, Bruton’s tyrosine kinase; BTKi, BTK inhibitor; CLL, chronic lymphocytic leukemia; CNS, central nervous system; iwCLL, International Workshop on CLL; NOTCH1, neurologic locus not

  8. Slide 8: Clinically Meaningful Objective Responses with Tolerable Safety Profile in R/R CLL

    CLL, chronic lymphocytic leukemia; CR, complete response; iwCLL, International Workshop on CLL; ORR, objective response rate; PD, progressive disease; PR, partial response; PR-L, partial response with rebound lymphocytosis; SD, stable disease Bexobrutideg overall response assessment: Phase 1a Clinic

  9. Slide 9: Advancing Bexobrutideg in CLL: Clinical Development Plan

    Advancing Bexobrutideg in CLL: Clinical Development Plan 9 Key summary points Positioned to lead a new class of therapeutics in CLL with best-in-class profile * Accelerated approval in the post-BTKi setting may be limited to the post-pirtobrutinib setting depending on evolving standard of care. BTKi

  10. Slide 10: Bexobrutideg Poised to Shape the Future Standard of Care in CLL

    BexobrutidegBTKi + BCL-2i 1 Initial opportunity in 2L+ CLL as monotherapy Bexobrutideg Poised to Shape the Future Standard of Care in CLL 10 BTKi Bexobrutideg 1L CLL 2L+ CLL Expansion opportunities as combo with BCL-2i 1L CLL 2L+ CLL BTKi +/- BCL-2i Bexobrutideg + BCL-2i Bexobrutideg + BCL-2i 1L, fi

  11. Slide 11: Confirmatory Phase 3 Trial for Full Approval

    • Single trial strategy to support global approval while maintaining capital efficiency • Investigator’s choice control arm ensures: − Clinical relevance across geographies − Addresses current and emerging standards of care − Maximizes enrollment opportunities Primary endpoint: PFS per iwCLL as asse

  12. Slide 12: Designed to Expand and Replace BTK Inhibitors in a $15B+ Global Market

    Designed to Expand and Replace BTK Inhibitors in a $15B+ Global Market 1.Total number of patients in major markets (US, EU4, UK, Japan) BTKis from Clarivate Decision Resources Group’s Disease Landscape & Forecast Report (2025) 2. BTKi Sales by Line of treatment for major markets (US, EU4, UK, Japan)

Nurix Therapeutics — Investor Presentation (September 2025) on 6ix